CD38 and Miyoshi myopathy: The results of a preclinical study showed that administering a combination of felzartamab and lemzoparlimab increased in vivo antitumor efficacy and in vitro ADCP in CD38-low and CD47-high R/R MM cells, which were resistant to daratumumab or felzartamab single-drug treatment (20).